675112-67-1 Usage
General Description
N-T-BOC-4,4-DIFLUOROCYCLOHEXYLAMINE is a chemical compound represented by the molecular formula C11H18F2N2O2. Commonly used in the field of organic synthesis, it belongs to the class of organic compounds known as tertiary amines. Its key feature is the BOC (tert-butoxycarbonyl) group, which is commonly used to protect amines from undesired chemical reactions during synthesis. The compound also features a cyclohexyl ring substituted with two fluorine atoms that could contribute to its reactivity and potential applications. As with many specialty chemicals, appropriate safety measures should be taken while handling, as the exact toxicity and potential hazards of this compound may not be fully known.
Check Digit Verification of cas no
The CAS Registry Mumber 675112-67-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,7,5,1,1 and 2 respectively; the second part has 2 digits, 6 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 675112-67:
(8*6)+(7*7)+(6*5)+(5*1)+(4*1)+(3*2)+(2*6)+(1*7)=161
161 % 10 = 1
So 675112-67-1 is a valid CAS Registry Number.
675112-67-1Relevant articles and documents
Iridinesulfonamide compound and use method thereof
-
, (2018/03/29)
An iridinesulfonamide compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity, pharmaceutically-acceptable salts, solvates or hydrates thereof, a pharmaceutical composition, as well as use of the compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition thereof in treating IDH1 mutation-induced cancers.
THERAPEUTICALLY ACTIVE COMPOUNDS AND USE THEREOF
-
, (2015/02/19)
Provided are therapeutically active compounds and the use in manufacture of medicaments for treating a cancer characterized by the presence of a mutant allele of IDH1.
THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
-
Page/Page column, (2015/03/31)
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
